Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 4
2006 1
2007 4
2008 3
2010 1
2011 2
2012 1
2013 4
2014 10
2015 13
2016 6
2017 8
2018 7
2019 16
2020 13
2021 11
2022 23
2023 32
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Agnelli G, et al. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. N Engl J Med. 2020. PMID: 32223112 Clinical Trial.
RESULTS: Recurrent venous thromboembolism occurred in 32 of 576 patients (5.6%) in the apixaban group and in 46 of 579 patients (7.9%) in the dalteparin group (hazard ratio, 0.63; 95% confidence interval [CI], 0.37 to 1.07; P<0.001 for noninferiority). Major bleeding oc …
RESULTS: Recurrent venous thromboembolism occurred in 32 of 576 patients (5.6%) in the apixaban group and in 46 of 579 patients (7.9%) in th …
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. McBane RD 2nd, et al. J Thromb Haemost. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. J Thromb Haemost. 2020. PMID: 31630479 Free article. Clinical Trial.
Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; hazard ratio (HR) not estimable because of 0 bleeding event in apixaban group]. Recurrent VTE occurred in 0.7% of apixaban, compared to 6.3% …
Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; …
Citicoline in acute ischemic stroke: A randomized controlled trial.
Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S, Upadhyay A, Goyal V, Singh MB, Gupta A, Rajan R, Srivastava MVP. Agarwal A, et al. PLoS One. 2022 May 31;17(5):e0269224. doi: 10.1371/journal.pone.0269224. eCollection 2022. PLoS One. 2022. PMID: 35639720 Free PMC article. Clinical Trial.
INTRODUCTION: Two pharmacological possibilities exist for an acute ischemic stroke (AIS): recanalization of the occluded artery and neuroprotection from ischaemic injury, the latter's efficacy being debatable. We sought to determine whether administration of Citicoline imm …
INTRODUCTION: Two pharmacological possibilities exist for an acute ischemic stroke (AIS): recanalization of the occluded artery and neuropro …
Limiting Mrs2-dependent mitochondrial Mg2+ uptake induces metabolic programming in prolonged dietary stress.
Madaris TR, Venkatesan M, Maity S, Stein MC, Vishnu N, Venkateswaran MK, Davis JG, Ramachandran K, Uthayabalan S, Allen C, Osidele A, Stanley K, Bigham NP, Bakewell TM, Narkunan M, Le A, Karanam V, Li K, Mhapankar A, Norton L, Ross J, Aslam MI, Reeves WB, Singh BB, Caplan J, Wilson JJ, Stathopulos PB, Baur JA, Madesh M. Madaris TR, et al. Cell Rep. 2023 Mar 28;42(3):112155. doi: 10.1016/j.celrep.2023.112155. Epub 2023 Feb 27. Cell Rep. 2023. PMID: 36857182 Free PMC article.
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study.
Yaghi S, Shu L, Mandel D, Leon Guerrero CR, Henninger N, Muppa J, Affan M, Ul Haq Lodhi O, Heldner MR, Antonenko K, Seiffge D, Arnold M, Salehi Omran S, Crandall R, Lester E, Lopez Mena D, Arauz A, Nehme A, Boulanger M, Touze E, Sousa JA, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito MT, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann JE, Engelter ST, Traenka C, Aguiar de Sousa D, Soares M, Rosa S, Zhou LW, Gandhi P, Field TS, Mancini S, Metanis I, Leker RR, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte CH, Choi R, MacDonald J, Bavarsad Shahripour R, Guo X, Ghannam M, Almajali M, Samaniego EA, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca AC, Baptista MF, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind DS, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy-Rivas R, Aziz Y, Bakradze E, Tran TL, Rodrigo-Gisbert M, Requena M, Saleh Velez F, Ortiz Gracia J, Mudassani V, de Havenon A, Vishnu VY, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Sieg… See abstract for full author list ➔ Yaghi S, et al. Stroke. 2024 Apr;55(4):908-918. doi: 10.1161/STROKEAHA.123.045731. Epub 2024 Feb 9. Stroke. 2024. PMID: 38335240 Free article.
In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45-1.12]; P …
In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associat …
Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
Pillai KS, Bhat P, Srivastava AK, Rajan R, Radhakrishnan DM, Elavarasi A, Srivastava MP, Singh MB, Vishnu VY, Prasad K, Pandit AK, Goyal V. Pillai KS, et al. Parkinsonism Relat Disord. 2022 Dec;105:1-6. doi: 10.1016/j.parkreldis.2022.10.017. Epub 2022 Oct 25. Parkinsonism Relat Disord. 2022. PMID: 36323130 Clinical Trial.
METHODS: This was a randomized, placebo-controlled, double-blind study. Parkinson's disease patients were allocated either to the intervention group (standard treatment along with Zonisamide 25 mg add-on) or the placebo group (standard treatment along with placebo). ...RES …
METHODS: This was a randomized, placebo-controlled, double-blind study. Parkinson's disease patients were allocated either to the int …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
Anti-inflammatory Activity of PLA2 Inhibitory Saccharumoside-B.
Sadhu SP, Yarla NS, Pragada RR, Konduri P. Sadhu SP, et al. Antiinflamm Antiallergy Agents Med Chem. 2022;21(2):121-134. doi: 10.2174/1871523021666220330143058. Antiinflamm Antiallergy Agents Med Chem. 2022. PMID: 35362396
RESULTS: Saccharumoside-B showed selective inhibition of the sPLA2 enzyme (IC50 = 7.53 0.232 muM), and thioetheramide-PC was used as a positive control. It showed significant inhibition (P 0.05) of TNF-alpha, IL-1beta, and IL-6 cytokines compared to the positive control de …
RESULTS: Saccharumoside-B showed selective inhibition of the sPLA2 enzyme (IC50 = 7.53 0.232 muM), and thioetheramide-PC was used as a posit …
Primary CNS vasculitis (PCNSV): a cohort study.
Agarwal A, Sharma J, Srivastava MVP, Sharma MC, Bhatia R, Dash D, Goyal V, Srivastava AK, Tripathi M, Suri V, Singh MB, Agarwal S, Sarkar C, Joseph L, Singh M, Suri A, Singh RK, Vibha D, Pandit AK, Rajan R, Gupta A, Elavarasi A, Radhakrishnan DM, Das A, Gaikwad S, Tandon V, Doddamani R, Upadhyay A, Garg A, Vishnu VY. Agarwal A, et al. Sci Rep. 2022 Aug 5;12(1):13494. doi: 10.1038/s41598-022-17869-7. Sci Rep. 2022. PMID: 35931755 Free PMC article.
Univariate and stepwise multiple logistic regression were applied. P-value<0.05 was considered statistically significant. The main outcome measures were documentation of clinical improvement or worsening (defined by mRS scores) and identification of independent predicto …
Univariate and stepwise multiple logistic regression were applied. P-value<0.05 was considered statistically significant. The main …
154 results